CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial (Q30444398)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial (English)

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

0 references

0 references

Crohn's disease

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Brian G. Feagan

2

object named as

Feagan BG

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

author name string

Sandborn WJ

1

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Radford-Smith G

3

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Kovacs A

4

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Enns R

5

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Innes A

6

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Patel J

7

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

language of work or name

0 references

publication date

1 October 2004

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

53

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

10

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

1485-1493

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774244

20 June 2018

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774244

20 June 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774244

20 June 2018

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774244

20 June 2018

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774244

20 June 2018

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774244

26 November 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774244

26 November 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774244

26 November 2018

Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/15361500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does self-administration of a quality of life index for inflammatory bowel disease change the results?

1 reference

https://pubmed.ncbi.nlm.nih.gov/15361500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/15361500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humanized antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15361500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15361500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUT.2003.035253

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30444398&oldid=1765224776"